NPS Pharmaceuticals sees FY13 net global Gattex sales approx. $31.5M

As of December 31, there were 303 patients on Gattex/Revestive as compared to 235 patients as of November 1. These results are in line with the company’s guidance of $28 to $32 million in net sales and 275 to 325 patients on therapy by the end of 2013. The company’s 2013 guidance for net sales and the number of patients expected on therapy by year-end were positively revised over the course of 2013.

Advertisement